Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot Study
Phase 2
- Conditions
- HBV-related acute liver failure
- Registration Number
- JPRN-UMIN000016148
- Lead Sponsor
- Hiroshima liver study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1)Autoimmune hepatitis 2)History of hypersensitivity to abatacept 3)Hepatic coma 4)HBV carrier 5)Serious infectious disease 6)Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method